| Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with Stage 2 hypertension. | |
| | |
MedLine Citation:
|
PMID: 22305998 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Previously, we reported the efficacy of aliskiren/amlodipine in US minority adults with stage 2 hypertension, with additional blood pressure (BP) lowering from the addition of hydrochlorothiazide (HCTZ). A subgroup analysis in patients with hypertension and comorbidities of diabetes, cardiometabolic syndrome, or obesity, and in black participants is reported. This 8-week, multicenter, double-blind study included 412 self-identified minority patients with mean sitting systolic BP (msSBP) ≥160 mm Hg and <200 mm Hg). Patients were randomized to receive either combination aliskiren/amlodipine 150/5 mg or amlodipine 5 mg. Doses were forced-titrated to a maximum of aliskiren/amlodipine/HCTZ 300/10/25 mg or aliskiren/amlodipine 300/10 mg, respectively. There were 256 black (62%), 118 diabetic (29%), 284 cardiometabolic syndrome (69%), and 249 obese (60%) randomized patients. Baseline msSBP was ∼167 mm Hg across all subgroups. Least-square mean reductions in msSBP, the primary efficacy outcome, from baseline to week 8 across all subgroups, ranged from 35 to 37 mm Hg with aliskiren/amlodipine/HCTZ and 28 to 30 mm Hg with aliskiren/amlodipine (P < .01 for all between-treatment comparisons). Both regimens were well tolerated. Among high-risk patients, such as diabetics or those with cardiometabolic syndrome, combination aliskiren/amlodipine is effective in lowering BP; the addition of HCTZ provided incremental BP-lowering efficacy while maintaining tolerability. However, because our subgroups were not mutually exclusive, the generalization of our findings to the population seen in clinical practice is limited. |
| | |
Authors:
|
Keith C Ferdinand; Richard Weitzman; Das Purkayastha; Kanaka Sridharan; Edgar A Jaimes |
Related Documents
:
|
19393838 - Nebivolol: a third-generation beta-blocker for hypertension. 9535588 - Beta-adrenergic blockade does not prevent polycythemia or decrease in plasma volume in ... 2886078 - Comparison of hemodynamic responses to isoproterenol infusion and surgical stress in pa... 1693718 - Vascular selectivity of felodipine: clinical experience. 3581168 - Hemodynamic monitoring and pacing with one catheter: a pilot study. 10412418 - Structural changes in rat aortic intima due to transmural pressure. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-2 |
Journal Detail:
|
Title: Journal of the American Society of Hypertension : JASH Volume: - ISSN: 1933-1711 ISO Abbreviation: - Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-6 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101312518 Medline TA: J Am Soc Hypertens Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 American Society of Hypertension. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Division of Cardiology, Tulane Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA; Association of Black Cardiologists, Inc., New Orleans, LA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intentional inhibition in human action: The power of 'no'
Next Document: Mitochondrial electron transport and glycolysis are coupled in articular cartilage.